MedTrace Logo

Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia

NCT00491569 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-06-26

No results posted yet for this study

Summary

Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.

The purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine, a GlyT-1 inhibitor, and D-serine, an NMDA-glycine site agonist, in chronically stable schizophrenia patients who have been stabilized with antipsychotics.

Conditions

  • Schizophrenias
  • Psychoses
  • Psychotic Disorders
  • Schizophrenic Disorders

Interventions

DRUG

Sarcosine and D-serine

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • National Health Research Institutes, Taiwan

    collaborator OTHER

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Hsien-Yuan Lane, MD,PhD · Department of Psychiatry, China Medical University Hospital, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2006-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491569 on ClinicalTrials.gov